

12/21/01

10023584

J1131 U.S. PTO

Please type a sign (+) inside this box + PTO/SB/05 (08-00)Approved for use through 10/31/2002 OMB 0651-0092  
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number10/023584  
12/21/01**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR ' 1.53(b))

Attorney Docket No PF112P1D2First Inventor ROSEN et al.Title Human Vascular Endothelial Growth Factor 2

Express Mail Label No

**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents

**ADDRESS TO:**Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

1. ☒ Fee Transmittal Form (e.g., PTO/SB/17) (in duplicate)  
(Submit an original, and a duplicate for fee processing)
2. ☐ Applicant claims small entity status.  
See 37 CFR 1.27.
3. ☒ Specification [Total Pages 45]  
(preferred arrangement set forth below)  
- Descriptive title of the Invention  
- Cross Reference to Related Applications  
- Statement Regarding Fed sponsored R & D  
- Reference to sequence listing, a table,  
or a computer program listing appendix  
- Background of the Invention  
- Brief Summary of the Invention  
- Brief Description of the Drawings (if filed)  
- Detailed Description  
- Claim(s)  
- Abstract of the Disclosure
4. ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets 14] (Figs 1A-9)
5. ☒ Declaration [Total Pages 4]  
a. ☐ Newly executed (original or copy)  
b. ☒ Copy from a prior application (37 CFR 1.63(d))  
(for continuation/divisional with Box 17 completed)  
i. ☐ **DELETION OF INVENTOR(S)**  
Signed statement attached deleting inventor(s) named in  
the prior application, see 37 CFR ' 1.63(d)(2) and 1.33(b)
6. ☒ Application Data Sheet. See 37 CFR 1.76. (3 pages)

7. ☐ CD-ROM or CD-R in duplicate, large table or Computer  
Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission  
(if applicable, all necessary)  
a. ☐ Computer Readable Form (CRF)  
b. Specification Sequence Listing on:  
i. ☐ CD-ROM or CD-R (2 copies); or  
ii. ☒ paper (8 pages)  
c. ☐ Statements verifying identity of above copies

**ACCOMPANYING APPLICATION PARTS**

9. ☒ Assignment Recordation Papers (cover sheet & documents (6 pp))
10. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
11. ☐ English Translation Document (if applicable)
12. ☒ Information Disclosure Statement/Form PTO/SB/08  
☒ Copies of References AA-FU and five (5) Statutory Declarations  
and accompanying exhibits
13. ☒ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503)  
(should be specifically itemized)
15. ☐ Certified copy of Priority Document(s)  
(if foreign priority is claimed)
16. ☒ **Other:** (a) Request Under 37 C.F.R. 1.821(e), and (b) Copy of  
Revocation by Assignee of Entire Interest/Revocation of Prior  
Power of Attorney from Appl. No. 08/465,968

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment,  
or in an Application Data Sheet under 37 CFR 1.76:☐ Continuation ☒ Divisional ☐ Continuation-in-Part (CIP) of prior application No. 08/465,968; filed June 6, 1995  
Prior application information Examiner Saoud, C. Group/Art Unit 1646**18. CORRESPONDENCE ADDRESS**☒ Customer Number or Bar Code Label22195or ☐ Correspondence address below

NAME

ADDRESS

CITY

STATE

ZIP CODE

COUNTRY

TELEPHONE

FAX

NAME (Print/Type)

Michele M. Wales

Registration No. (Attorney/Agent)

43,975

SIGNATURE

Michele M. Wales

Date

12/21/01r Statement: this form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete  
ould be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO  
mmmissioner for Patents, Box Patent Application, Washington, DC 20231

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Rosen et al.

Application Serial No.: Unassigned

Art Unit: unassigned

Filed: Herewith

Examiner: unassigned

For: **Human Vascular Endothelial Growth  
Factor 2**

Attorney Docket No.: PF112P1D2

**REQUEST UNDER 37 C.F.R. § 1.821(e)**

Assistant Commissioner for Patents  
Washington, D.C. 20231


Sir :

The above-identified patent application is a divisional of application Serial No. 08/465,968, filed June 6, 1995. The sequence listing of the instant application is identical to the sequence content of the computer readable sequence listing filed in connection with Application Serial No. 08/465,968, on December 9, 1998.

In accordance with 37 C.F.R. § 1.821(e), please use the computer readable form filed on December 9, 1998 in connection with application Serial No. 08/465,968 as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the original and Substitute Sequence Listing is included in the specification of the instant application filed herewith. Applicants hereby certify that the paper copy of the Substitute Sequence Listing filed herewith and the computer readable sequence listing filed on December 9, 1998 in connection with application Serial No. 08/465,968 are the same and do not include new matter.

Respectfully submitted,

Dated: 12/21/01

  
Michele M. Wales (Reg. No. 43,975)  
Attorney for Applicants

**Human Genome Sciences, Inc.**  
9410 Key West Avenue  
Rockville, MD 20850  
(301) 610-5772 (telephone)

Enclosure  
MMW/AKR/lcc